90%Confidence
0Views
FDASource
2026-03-28Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance failures poses significant patient safety risks for this high-demand diabetes/weight loss medication. This regulatory action could temporarily disrupt supply in a competitive market and damage the company's reputation for quality control.
Actionable: Assess alternative Semaglutide suppliers and monitor for potential market share shifts to competitors with more reliable manufacturing.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now